|
|
|
Insider
Information: |
Tammenoms Bakker Juliet |
Relationship: |
|
City: |
Menlo Park |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
10 |
|
Direct
Shares |
195,546 |
|
Indirect Shares
|
34,191,873 |
|
|
Direct
Value |
$7,122,255 |
|
|
Indirect Value
|
$686,832,987 |
|
|
Total
Shares |
34,387,419 |
|
|
Total
Value |
$693,955,243 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
6
|
13
|
Stock
price went up :
|
3
|
12
|
Stock
price went down : |
3
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
12.0
|
Percentage
Gain/Loss : |
7.6%
|
1,146.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Corcept Therapeutics Inc |
CORT |
10% Owner |
2016-12-15 |
133,539 |
2016-12-15 |
10,956,002 |
Premium* |
|
Esperion Therapeutics, Inc. |
ESPR |
10% Owner |
2013-07-01 |
0 |
2014-11-18 |
28,186 |
Premium* |
|
Aimmune Therapeutics, Inc. |
AIMT |
10% Owner |
2018-02-22 |
16,651 |
2018-02-22 |
6,013,134 |
Premium* |
|
Molecular Templates, Inc. |
MTEM |
10% Owner |
2018-09-21 |
0 |
2020-08-28 |
3,202,530 |
Premium* |
|
Axonics Modulation Technologies,... |
AXNX |
Director |
2020-09-18 |
3,500 |
2020-09-18 |
1,956,359 |
Premium* |
|
Venus Concept Inc |
VERO |
Director, 10% Owner |
2019-11-07 |
0 |
2019-11-07 |
3,666,119 |
Premium* |
|
Eargo, Inc. |
EAR |
Director, 10% Owner |
2021-05-17 |
7,016 |
2021-05-17 |
3,008 |
Premium* |
|
Tourmaline Bio |
TRML |
10% Owner |
2021-05-11 |
0 |
2021-05-11 |
3,220,775 |
Premium* |
|
Vera Therapeutics, Inc. |
VERA |
10% Owner |
2021-05-18 |
0 |
2023-02-06 |
5,144,212 |
Premium* |
|
Rxsight, Inc. |
RXST |
|
2024-05-17 |
34,840 |
2024-05-17 |
1,548 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
97 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
EAR |
Eargo, Inc. |
Director |
|
2020-10-20 |
4 |
B |
$18.00 |
$4,199,994 |
I/I |
233,333 |
3,918,691 |
2.25 |
- |
|
EAR |
Eargo, Inc. |
Director |
|
2021-04-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,508 |
3,508 |
0 |
- |
|
EAR |
Eargo, Inc. |
Director |
|
2021-04-14 |
4 |
A |
$0.00 |
$0 |
I/I |
1,504 |
1,504 |
0 |
- |
|
EAR |
Eargo, Inc. |
Director |
|
2021-04-14 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,000,000) |
2,918,691 |
0 |
- |
|
TRML |
Tourmaline Bio |
10% Owner |
|
2021-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,985,775 |
2,985,775 |
0 |
- |
|
TRML |
Tourmaline Bio |
10% Owner |
|
2021-05-11 |
4 |
B |
$17.00 |
$3,995,000 |
I/I |
235,000 |
3,220,775 |
1.5 |
- |
|
EAR |
Eargo, Inc. |
Director |
|
2021-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,508 |
7,016 |
0 |
- |
|
EAR |
Eargo, Inc. |
Director |
|
2021-05-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,000,000) |
1,918,691 |
0 |
- |
|
EAR |
Eargo, Inc. |
Director |
|
2021-05-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,504 |
3,008 |
0 |
- |
|
VERA |
Vera Therapeutics, Inc. |
10% Owner |
|
2021-05-18 |
4 |
B |
$11.00 |
$9,999,990 |
I/I |
909,090 |
3,096,594 |
1.5 |
- |
|
VERA |
Vera Therapeutics, Inc. |
10% Owner |
|
2021-05-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,187,504 |
2,187,504 |
0 |
- |
|
RXST |
Rxsight, Inc. |
Director |
|
2021-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,859 |
5,859 |
0 |
- |
|
RXST |
Rxsight, Inc. |
Director |
|
2021-08-03 |
4 |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
500,000 |
2.1 |
% |
|
RXST |
Rxsight, Inc. |
Director |
|
2021-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
1,863,613 |
1,863,613 |
0 |
- |
|
RXST |
Rxsight, Inc. |
Director |
|
2021-08-03 |
4 |
B |
$16.00 |
$200,000 |
D/D |
12,500 |
18,359 |
2.39 |
% |
|
VERA |
Vera Therapeutics, Inc. |
10% Owner |
|
2022-02-10 |
4 |
B |
$15.00 |
$4,999,995 |
I/I |
333,333 |
3,429,927 |
1.5 |
- |
|
RXST |
Rxsight, Inc. |
Director |
|
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,349 |
28,708 |
0 |
- |
|
VERA |
Vera Therapeutics, Inc. |
10% Owner |
|
2023-02-06 |
4 |
B |
$7.00 |
$11,999,995 |
I/I |
1,714,285 |
1,714,285 |
1.5 |
- |
|
RXST |
Rxsight, Inc. |
Director |
|
2023-02-10 |
4 |
B |
$12.50 |
$6,000,000 |
I/I |
480,000 |
980,000 |
2.1 |
% |
|
RXST |
Rxsight, Inc. |
Director |
|
2023-05-26 |
4 |
D |
$0.00 |
$0 |
I/I |
(497,150) |
1,491,463 |
0 |
- |
|
RXST |
Rxsight, Inc. |
Director |
|
2023-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
33,135 |
61,843 |
0 |
- |
|
RXST |
Rxsight, Inc. |
Director |
|
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,731 |
67,574 |
0 |
- |
|
RXST |
Rxsight, Inc. |
Director |
|
2023-06-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(267,300) |
712,700 |
0 |
- |
|
RXST |
Rxsight, Inc. |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,022 |
68,596 |
0 |
- |
|
RXST |
Rxsight, Inc. |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
I/I |
439 |
439 |
0 |
- |
|
97 Records found
|
|
Page 3 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|